Best SARMs for Research 2026 | RAD-140, LGD-4033, Ostarine, MK-677 Compared

Best SARMs for Research 2026

RAD-140, LGD-4033, Ostarine, MK-677, YK-11, and Cardarine compared by mechanism, clinical data, selectivity, and research application — for qualified investigators.

Published April 10, 2026 · Rainbow Peptide Research Team

For Research Use Only (RUO). Not for human consumption or therapeutic use.

How to Choose a SARM for Your Research

The "best" SARM depends entirely on the research question. This guide categorizes SARMs by their primary research utility based on available published data.

Best for Muscle Wasting Research: LGD-4033 & Ostarine

If your research requires translational relevance to human muscle wasting:

LGD-4033 (Ligandrol): Highest potency per dose of any SARM in human data. Basaria et al. (2013): +1.21 kg lean mass at 1 mg/day in 21 days. Viking hip fracture Phase II confirms functional improvement. Best choice for potency-focused muscle wasting models. Read LGD-4033 guide →
Ostarine (MK-2866): Phase II and III cancer cachexia data — the most extensive clinical dataset in the class. Phase III data (POWER 1/2) in NSCLC patients provides important translational benchmarks. Best choice when clinical data comparability matters. Read Ostarine guide →

Best for GH/IGF-1 Axis Research: MK-677

MK-677 (Ibutamoren): Oral ghrelin receptor agonist with 2-year human RCT data showing sustained lean mass and IGF-1 elevation. Only oral compound in the SARM-adjacent category with this depth of clinical data. Ideal for chronic GH/IGF-1 research protocols without injectable requirements. Read MK-677 guide →

Best for Neuroprotection Research: RAD-140

RAD-140 (Testolone): Three published neuroprotection studies (Aβ toxicity, HER2+ cancer, spatial memory in aged rats). No other SARM has comparable neuroprotection literature. Best choice for CNS/AR-mediated neuroprotection research. Read RAD-140 guide →

Best for Metabolic/Endurance Research: Cardarine, SR9009, SLU-PP-332

These compounds are grouped with SARMs commercially but target metabolic pathways:

Cardarine (GW501516): PPARδ agonist — most potent fat oxidation and endurance effect in exercise mimetic research (Narkar et al.: +44-77% treadmill distance). Important note: carcinogenicity signals in 2-year rodent studies — institutional biosafety review required for in vivo use. Read Cardarine guide →
SR9009 (Stenabolic): Rev-erb agonist — circadian biology and metabolic regulation. Distinct mechanism from both PPARδ and ERR pathways.
SLU-PP-332: Pan-ERR agonist — mitochondrial biogenesis and cardiac protection. Better carcinogenicity profile than Cardarine for chronic in vivo studies. Read SLU-PP-332 guide →

Best for Myostatin/Unique Mechanism Research: YK-11

YK-11: Unique dual mechanism — partial AR agonism plus follistatin induction leading to myostatin inhibition. The only SARM with documented myostatin pathway activity. Best choice for research designs requiring both AR agonism and myostatin biology.

Full Comparison Table

SARM	Mechanism	Best Research Use	Human Data	Selectivity
LGD-4033	AR agonist	Muscle wasting (highest potency)	Phase II (lean mass, hip fx)	~500:1
Ostarine	AR agonist	Cancer cachexia (most clinical data)	Phase III (cachexia)	~3:1
RAD-140	AR agonist	Neuroprotection, muscle	Phase I	~89:1
MK-677	Ghrelin receptor	GH/IGF-1 axis, aging	Phase II (2-yr RCT)	N/A (not AR)
YK-11	AR + follistatin	Myostatin biology	In vitro only	Steroidal
Cardarine	PPARδ	Fat oxidation, endurance	Phase IIa (dyslipidemia)	N/A (not AR)
SR9009	Rev-erb	Circadian, metabolic	Preclinical only	N/A (not AR)
Andarine	AR agonist	Bone density, AR selectivity	Preclinical	High bone selectivity

Frequently Asked Questions

What is the best SARM for muscle wasting research?

For muscle wasting research, LGD-4033 and Ostarine (MK-2866) are the most appropriate choices based on available clinical data. LGD-4033 showed +1.21 kg lean mass at 1 mg/day in 21 days (Basaria et al., 2013) — the most potent lean mass effect per dose of any SARM in a human clinical trial. Ostarine has Phase II and Phase III trial data in cancer cachexia (the most extensive clinical dataset of any SARM). If translational relevance and clinical data are priorities, Ostarine is the best-characterized option. If potency per dose is the priority, LGD-4033 has the stronger lean mass data.

Which SARM has the most clinical research data?

Ostarine (MK-2866, Enobosarm) has the most extensive clinical research data of any SARM — it reached Phase III clinical trials in cancer cachexia (POWER 1 and POWER 2), further than any other SARM compound. MK-677 (Ibutamoren) also has extensive clinical data including a 2-year randomized controlled trial (Nass et al., 2008), though it is technically a ghrelin receptor agonist rather than a true SARM. LGD-4033 has important Phase II data (Basaria et al., 2013 and Viking VK5211 hip fracture trial).

What are the best SARMs for bone density research?

For bone density research models, Ostarine and LGD-4033 are the best-characterized. Ostarine has published bone mineral density data in postmenopausal women (Dalton et al., 2011). LGD-4033 (VK5211) showed bone biomarker effects in the Viking hip fracture trial. MK-677 also has bone density data via IGF-1 elevation. Andarine (S4) has strong preclinical data in ovariectomized rat osteoporosis models. The choice depends on whether human data (Ostarine, LGD-4033, MK-677) or selective bone-tissue targeting (Andarine) is the research priority.